FDA Targets GLP 1 and Peptide Compounding, Advertising and 'Research Use Only' Labeling FDA warning letters target marketers of unapproved weight loss drugs RAPS Is BPC 157 Banned? Oral vs. Injectable Forms Explained FDA to weigh easing limits on unproven peptides favored by RFK Jr. and MAHA supporters PBS News BPC 157 Erectile Dysfunction Study: What the Evidence Actually Shows On August 15 2025, the U.S. Food & Drug Administration (FDA) issued a Warning Letter to Platinum Biologics LLC for marketing umbilicalcordderived products including exosome products (NanoEx & Nano Xsomes) without approval.